Sexual health is a fundamental component of overall wellbeing, yet it remains one of the most under-researched and under-discussed areas of medicine. Sexual dysfunction affects a significant proportion of the Australian population — studies suggest that approximately 40% of Australian women and 20% of Australian men experience some form of sexual difficulty during their lifetime. Despite these numbers, treatment options remain limited, particularly for conditions involving desire and arousal.
Sexual wellness peptides represent a paradigm shift in how researchers approach sexual health. Rather than targeting peripheral vascular mechanisms (as drugs like sildenafil do), these peptides work through central nervous system pathways that regulate sexual desire and arousal at their source — the brain. This central mechanism of action makes them uniquely valuable for research into conditions where desire, rather than physical function, is the primary concern.
In this comprehensive guide, we explore two groundbreaking sexual wellness peptides available for research in Australia: PT-141 (Bremelanotide) and Kisspeptin-10. Each works through distinct neuroendocrine pathways, and together they represent the cutting edge of sexual health research.
Sexual function is regulated by a complex interplay of neural, hormonal, vascular, and psychological factors. At the neurological level, sexual desire and arousal are mediated by several key brain regions, including the hypothalamus, limbic system, and prefrontal cortex. These regions communicate through neurotransmitter systems involving dopamine, oxytocin, melanocortins, and kisspeptin — each playing a distinct role in the sexual response cycle.
The melanocortin system, which includes melanocortin receptors MC3R and MC4R in the hypothalamus, has emerged as a critical regulator of sexual function. Research published in the Proceedings of the National Academy of Sciences has demonstrated that activation of hypothalamic melanocortin receptors can initiate sexual arousal responses in both males and females, independent of hormonal status.
Similarly, the kisspeptin system — centred on kisspeptin neurons in the hypothalamus — has been identified as a master regulator of reproductive function. Kisspeptin neurons integrate metabolic, environmental, and hormonal signals to control the release of gonadotropin-releasing hormone (GnRH), which in turn regulates the entire reproductive hormone cascade.
PT-141 (10mg) is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors, particularly MC3R and MC4R. Originally developed from the tanning peptide Melanotan II, PT-141 was found to have potent pro-sexual effects that were independent of its melanogenic (tanning) activity. This discovery led to its development as a dedicated sexual wellness compound.
PT-141 works through a fundamentally different mechanism than traditional erectile dysfunction medications. While PDE5 inhibitors like sildenafil act on peripheral blood vessels to facilitate erection, PT-141 acts centrally — in the brain — to activate the melanocortin system and initiate sexual arousal. This central mechanism means PT-141 can influence sexual desire and arousal, not just physical sexual response.
When PT-141 binds to MC4R receptors in the hypothalamus, it triggers a signalling cascade that activates downstream pathways involved in sexual arousal, including dopaminergic and oxytocinergic systems. Research published in the Journal of Sexual Medicine has demonstrated that this central activation produces measurable increases in sexual desire, arousal, and satisfaction in both men and women.
PT-141’s journey from research peptide to approved pharmaceutical is a remarkable success story. In 2019, the U.S. FDA approved bremelanotide (marketed as Vyleesi) for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women — making it the first centrally-acting agent approved for female sexual dysfunction.
Clinical trials demonstrated that PT-141 significantly increased sexual desire and reduced distress associated with low sexual desire in women with HSDD. The RECONNECT trials showed that women treated with PT-141 experienced meaningful improvements in desire, arousal, and overall sexual satisfaction compared to placebo. Importantly, these effects were observed regardless of the type of sexual activity, suggesting that PT-141 enhances the fundamental neurological substrate of sexual desire rather than facilitating a specific physical response.
In male sexual health research, PT-141 has shown efficacy in men with erectile dysfunction who did not respond to PDE5 inhibitors. A study published in Urology demonstrated that PT-141 produced erections in men with ED, including those who had failed sildenafil therapy. This finding is significant because it suggests that central melanocortin activation can overcome peripheral vascular limitations — opening new research avenues for treatment-resistant ED.
PT-141 research has also explored the peptide’s effects on sexual motivation and reward. Animal studies have shown that PT-141 can increase sexual motivation (as measured by approach behaviour and partner preference) without affecting general locomotor activity, suggesting a specific effect on sexual reward pathways rather than a non-specific stimulant effect.
Kisspeptin-10 (10mg) is a truncated form of the kisspeptin peptide family, consisting of the 10 C-terminal amino acids of the full-length kisspeptin-54 molecule. Despite its smaller size, Kisspeptin-10 retains full biological activity at the kisspeptin receptor (KISS1R, also known as GPR54), making it a powerful tool for reproductive and sexual health research.
Kisspeptin-10 acts on KISS1R receptors located on GnRH neurons in the hypothalamus. When Kisspeptin-10 binds to these receptors, it stimulates the release of GnRH, which in turn triggers the release of luteinising hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland. This cascade is fundamental to reproductive function, controlling everything from puberty onset to ovulation, spermatogenesis, and sex hormone production.
Research published in the Journal of Clinical Investigation established kisspeptin as the most potent known stimulator of GnRH release, positioning it as a master regulator of the reproductive axis. Mutations in the KISS1R gene cause hypogonadotropic hypogonadism — a condition characterised by absent puberty and infertility — underscoring the critical importance of kisspeptin signalling for reproductive function.
Kisspeptin-10 research has produced groundbreaking findings across multiple areas of reproductive and sexual health. In fertility research, studies have demonstrated that Kisspeptin-10 can stimulate LH release in both men and women, with potential applications in assisted reproduction. A landmark study published in the Journal of Clinical Investigation showed that kisspeptin administration could trigger oocyte maturation in women undergoing IVF, offering a potentially safer alternative to traditional hCG triggers that carry a risk of ovarian hyperstimulation syndrome.
In sexual health research, Kisspeptin-10 has shown fascinating effects on sexual arousal and attraction. Research conducted at Imperial College London and published in the Journal of Clinical Investigation demonstrated that kisspeptin administration enhanced brain activity in regions associated with sexual arousal and romantic attraction when participants viewed sexual and romantic images. Importantly, kisspeptin also reduced negative mood, suggesting a dual effect on sexual function and emotional wellbeing.
These findings have positioned kisspeptin as a potential treatment for psychosexual disorders — conditions where psychological factors impair sexual function. Unlike PT-141, which primarily targets the melanocortin system, kisspeptin appears to modulate the emotional and psychological dimensions of sexual response, making it a complementary research tool for understanding the full spectrum of sexual function.
Kisspeptin-10 has also been investigated for its role in metabolic regulation. Research has shown that kisspeptin neurons integrate metabolic signals (including leptin and insulin) with reproductive function, providing a molecular explanation for the well-known link between metabolic health and fertility. These findings have implications for research into polycystic ovary syndrome (PCOS), obesity-related infertility, and hypothalamic amenorrhoea.
PT-141 and Kisspeptin-10 target different but interconnected aspects of sexual function. PT-141 acts through the melanocortin system to directly activate sexual arousal pathways, while Kisspeptin-10 works through the reproductive neuroendocrine axis to modulate both hormonal function and the emotional dimensions of sexual response.
For researchers investigating sexual desire and arousal, PT-141 provides a direct tool for activating central arousal pathways. For those studying the broader neuroendocrine regulation of reproductive and sexual function, Kisspeptin-10 offers insights into how the brain integrates metabolic, hormonal, and emotional signals to regulate sexual behaviour.
Australia has a strong tradition of sexual health research, with institutions like the Kirby Institute at UNSW and the Melbourne Sexual Health Centre contributing significantly to the global understanding of sexual health and dysfunction. However, research into the neuroscience of sexual desire and arousal — the domain where peptides like PT-141 and Kisspeptin-10 operate — remains relatively underdeveloped compared to research on sexually transmitted infections and reproductive health.
The growing recognition that sexual dysfunction has significant impacts on quality of life, mental health, and relationship satisfaction is driving increased research investment in this area. Peptide-based approaches offer particularly promising avenues because they target the central mechanisms of sexual function, potentially addressing conditions that have been resistant to existing treatments.
Researchers exploring related areas may also find value in our anti-ageing peptides, as age-related hormonal changes are a major contributor to sexual dysfunction, or our cognitive peptides like Selank, which can address the anxiety and stress that often underlie psychosexual disorders.
Sexual wellness peptides represent a transformative approach to understanding and addressing sexual health challenges. PT-141‘s proven ability to activate central sexual arousal pathways and Kisspeptin-10‘s role as a master regulator of reproductive neuroendocrine function provide Australian researchers with powerful tools for advancing sexual health science.
As our understanding of the neuroscience of sexual function deepens, these peptides will play an increasingly important role in developing effective, targeted interventions for sexual dysfunction. Explore our complete range of sexual wellness peptides and contribute to the advancement of sexual health research in Australia.
Australia’s leading supplier of high-purity research peptides. Committed to scientific excellence and fast, secure domestic distribution.
Research Disclaimer: All products sold by Aus Bio Peps are strictly for laboratory research and development purposes only. These products are not for human consumption, medical, or diagnostic use. Please consult the TGA guidelines regarding research chemicals.
© 2026 Aus Bio Peps. All Rights Reserved. Based in Australia.
